Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

Kilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, Emanuela Romano, Marnix Geukes Foppen, Jianda Yuan, Michael Postow, Phillip Wong, Domenico Mallardo, Bastian Schilling, Anna Maria Di Giacomo, Amir Khammari, Brigitte Dreno, Michele Maio, Dirk Schadendorf, Paolo A. Ascierto, Jedd D. Wolchok, Christian U. Blank, Claus Garbe, Graham PawelecBenjamin Weide

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The role of the assessment of peripheral T-cell phenotypes in predicting overall survival (OS) after ipilimumab treatment is unclear. Here, we analysed mononuclear cells in the blood before and at different time points during treatment with ipilimumab in 137 late-stage melanoma patients. The proportions of baseline naïve and memory T-cells were measured by flow cytometry and correlated with OS, with an emphasis on PD-1 expression. High frequencies (>13%) of CD8 effector-memory type 1 (EM1) T-cells at baseline correlated with longer OS (p = 0.029) and higher clinical response rates (p = 0.01). The frequency of these EM1 cells and the M category had independent impacts on OS (hazard ratio = 1.5, p = 0.033; and hazard ratio = 1.9, p = 0.007). In contrast, high baseline frequencies of late stage-differentiated effector memory CD8 cells (>23.8%) were negatively associated with OS (p = 0.034) but did not correlate with clinical response. Following treatment, a decrease of CD8 cells from baseline to the time of the second drug dose and at later time points was strongly and consistently correlated with a high clinical response rate. Our observations thus suggest an important predictive role of baseline CD8 EM1 cells and changes in CD8 cells for clinical response of ipilimumab. Further validation of these biomarker candidates is warranted.

Original languageEnglish
Pages (from-to)61-70
Number of pages10
JournalEuropean Journal of Cancer
Volume73
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Melanoma
T-Lymphocytes
Survival
Blood Cells
Flow Cytometry
Therapeutics
Biomarkers
ipilimumab
Phenotype
Pharmaceutical Preparations

Keywords

  • Biomarker
  • Effector memory cells
  • Ipilimumab
  • Melanoma
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., ... Weide, B. (2017). Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 73, 61-70. https://doi.org/10.1016/j.ejca.2016.12.011

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. / Wistuba-Hamprecht, Kilian; Martens, Alexander; Heubach, Florian; Romano, Emanuela; Geukes Foppen, Marnix; Yuan, Jianda; Postow, Michael; Wong, Phillip; Mallardo, Domenico; Schilling, Bastian; Giacomo, Anna Maria Di; Khammari, Amir; Dreno, Brigitte; Maio, Michele; Schadendorf, Dirk; Ascierto, Paolo A.; Wolchok, Jedd D.; Blank, Christian U.; Garbe, Claus; Pawelec, Graham; Weide, Benjamin.

In: European Journal of Cancer, Vol. 73, 01.03.2017, p. 61-70.

Research output: Contribution to journalArticle

Wistuba-Hamprecht, K, Martens, A, Heubach, F, Romano, E, Geukes Foppen, M, Yuan, J, Postow, M, Wong, P, Mallardo, D, Schilling, B, Giacomo, AMD, Khammari, A, Dreno, B, Maio, M, Schadendorf, D, Ascierto, PA, Wolchok, JD, Blank, CU, Garbe, C, Pawelec, G & Weide, B 2017, 'Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients', European Journal of Cancer, vol. 73, pp. 61-70. https://doi.org/10.1016/j.ejca.2016.12.011
Wistuba-Hamprecht, Kilian ; Martens, Alexander ; Heubach, Florian ; Romano, Emanuela ; Geukes Foppen, Marnix ; Yuan, Jianda ; Postow, Michael ; Wong, Phillip ; Mallardo, Domenico ; Schilling, Bastian ; Giacomo, Anna Maria Di ; Khammari, Amir ; Dreno, Brigitte ; Maio, Michele ; Schadendorf, Dirk ; Ascierto, Paolo A. ; Wolchok, Jedd D. ; Blank, Christian U. ; Garbe, Claus ; Pawelec, Graham ; Weide, Benjamin. / Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. In: European Journal of Cancer. 2017 ; Vol. 73. pp. 61-70.
@article{f75a3b9f879947818fec94f2284e6a5d,
title = "Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients",
abstract = "The role of the assessment of peripheral T-cell phenotypes in predicting overall survival (OS) after ipilimumab treatment is unclear. Here, we analysed mononuclear cells in the blood before and at different time points during treatment with ipilimumab in 137 late-stage melanoma patients. The proportions of baseline na{\"i}ve and memory T-cells were measured by flow cytometry and correlated with OS, with an emphasis on PD-1 expression. High frequencies (>13{\%}) of CD8 effector-memory type 1 (EM1) T-cells at baseline correlated with longer OS (p = 0.029) and higher clinical response rates (p = 0.01). The frequency of these EM1 cells and the M category had independent impacts on OS (hazard ratio = 1.5, p = 0.033; and hazard ratio = 1.9, p = 0.007). In contrast, high baseline frequencies of late stage-differentiated effector memory CD8 cells (>23.8{\%}) were negatively associated with OS (p = 0.034) but did not correlate with clinical response. Following treatment, a decrease of CD8 cells from baseline to the time of the second drug dose and at later time points was strongly and consistently correlated with a high clinical response rate. Our observations thus suggest an important predictive role of baseline CD8 EM1 cells and changes in CD8 cells for clinical response of ipilimumab. Further validation of these biomarker candidates is warranted.",
keywords = "Biomarker, Effector memory cells, Ipilimumab, Melanoma, Prognosis",
author = "Kilian Wistuba-Hamprecht and Alexander Martens and Florian Heubach and Emanuela Romano and {Geukes Foppen}, Marnix and Jianda Yuan and Michael Postow and Phillip Wong and Domenico Mallardo and Bastian Schilling and Giacomo, {Anna Maria Di} and Amir Khammari and Brigitte Dreno and Michele Maio and Dirk Schadendorf and Ascierto, {Paolo A.} and Wolchok, {Jedd D.} and Blank, {Christian U.} and Claus Garbe and Graham Pawelec and Benjamin Weide",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.ejca.2016.12.011",
language = "English",
volume = "73",
pages = "61--70",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

AU - Wistuba-Hamprecht, Kilian

AU - Martens, Alexander

AU - Heubach, Florian

AU - Romano, Emanuela

AU - Geukes Foppen, Marnix

AU - Yuan, Jianda

AU - Postow, Michael

AU - Wong, Phillip

AU - Mallardo, Domenico

AU - Schilling, Bastian

AU - Giacomo, Anna Maria Di

AU - Khammari, Amir

AU - Dreno, Brigitte

AU - Maio, Michele

AU - Schadendorf, Dirk

AU - Ascierto, Paolo A.

AU - Wolchok, Jedd D.

AU - Blank, Christian U.

AU - Garbe, Claus

AU - Pawelec, Graham

AU - Weide, Benjamin

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The role of the assessment of peripheral T-cell phenotypes in predicting overall survival (OS) after ipilimumab treatment is unclear. Here, we analysed mononuclear cells in the blood before and at different time points during treatment with ipilimumab in 137 late-stage melanoma patients. The proportions of baseline naïve and memory T-cells were measured by flow cytometry and correlated with OS, with an emphasis on PD-1 expression. High frequencies (>13%) of CD8 effector-memory type 1 (EM1) T-cells at baseline correlated with longer OS (p = 0.029) and higher clinical response rates (p = 0.01). The frequency of these EM1 cells and the M category had independent impacts on OS (hazard ratio = 1.5, p = 0.033; and hazard ratio = 1.9, p = 0.007). In contrast, high baseline frequencies of late stage-differentiated effector memory CD8 cells (>23.8%) were negatively associated with OS (p = 0.034) but did not correlate with clinical response. Following treatment, a decrease of CD8 cells from baseline to the time of the second drug dose and at later time points was strongly and consistently correlated with a high clinical response rate. Our observations thus suggest an important predictive role of baseline CD8 EM1 cells and changes in CD8 cells for clinical response of ipilimumab. Further validation of these biomarker candidates is warranted.

AB - The role of the assessment of peripheral T-cell phenotypes in predicting overall survival (OS) after ipilimumab treatment is unclear. Here, we analysed mononuclear cells in the blood before and at different time points during treatment with ipilimumab in 137 late-stage melanoma patients. The proportions of baseline naïve and memory T-cells were measured by flow cytometry and correlated with OS, with an emphasis on PD-1 expression. High frequencies (>13%) of CD8 effector-memory type 1 (EM1) T-cells at baseline correlated with longer OS (p = 0.029) and higher clinical response rates (p = 0.01). The frequency of these EM1 cells and the M category had independent impacts on OS (hazard ratio = 1.5, p = 0.033; and hazard ratio = 1.9, p = 0.007). In contrast, high baseline frequencies of late stage-differentiated effector memory CD8 cells (>23.8%) were negatively associated with OS (p = 0.034) but did not correlate with clinical response. Following treatment, a decrease of CD8 cells from baseline to the time of the second drug dose and at later time points was strongly and consistently correlated with a high clinical response rate. Our observations thus suggest an important predictive role of baseline CD8 EM1 cells and changes in CD8 cells for clinical response of ipilimumab. Further validation of these biomarker candidates is warranted.

KW - Biomarker

KW - Effector memory cells

KW - Ipilimumab

KW - Melanoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85012241936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012241936&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2016.12.011

DO - 10.1016/j.ejca.2016.12.011

M3 - Article

AN - SCOPUS:85012241936

VL - 73

SP - 61

EP - 70

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -